Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options

Rhea-AI Filing Summary

Fate Therapeutics director Robert S. Epstein exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. The options related to shares that vested on the date of the company’s 2017 Annual Meeting of Stockholders. After the transaction, he directly holds 36,331 Fate Therapeutics shares.

Insider Trade Summary

25,000 shares exercised/converted

Mixed 2 txns

Insider EPSTEIN ROBERT S

Role null

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,000	$0.00	--
Exercise	Common Stock	25,000	$1.69	$42K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 36,331 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options exercised: 25,000 shares Exercise price: $1.69 per share Shares owned after: 36,331 shares +2 more

5 metrics

Options exercised 25,000 shares Common Stock acquired via option exercise on May 5, 2026

Exercise price $1.69 per share Strike price for 25,000 Fate Therapeutics options

Shares owned after 36,331 shares Direct Fate Therapeutics holdings following the transaction

Derivative position after 0 options Stock Option (Right to Buy) balance after exercise

Option expiration date May 11, 2026 Original expiration date for exercised options

Key Terms

Stock Option (Right to Buy), derivative security, vested and became exercisable, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vested and became exercisable financial

""The shares subject to the option vested and became exercisable""

Annual Meeting of Stockholders financial

""on the date of the 2017 Annual Meeting of Stockholders""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EPSTEIN ROBERT S

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		M		25,000	A	$1.69	36,331	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.69	05/05/2026		M		25,000		(1)	05/11/2026	Common Stock	25,000	$0.00	0	D

Explanation of Responses:

1. The shares subject to the option vested and became exercisable on the date of the 2017 Annual Meeting of Stockholders.

	/s/ Cindy Tahl, as Attorney-in-Fact	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did FATE director Robert S. Epstein report?

Robert S. Epstein reported exercising stock options to acquire 25,000 shares of Fate Therapeutics common stock. The options were exercised at $1.69 per share, converting a derivative position into direct share ownership and increasing his directly held stake in the company.

At what price were Robert S. Epstein’s Fate Therapeutics options exercised?

The Fate Therapeutics stock options were exercised at $1.69 per share. This represents the strike price set for the option grant, which defines the cost per share when converting the option into common stock upon exercise by the director.

How many Fate Therapeutics shares does Robert S. Epstein own after this Form 4?

Following the reported option exercise, Robert S. Epstein directly owns 36,331 shares of Fate Therapeutics common stock. This post-transaction figure reflects his updated direct equity position after converting 25,000 stock options into common shares.

What happened to the 25,000 Fate Therapeutics stock options after exercise?

The 25,000 Fate Therapeutics stock options were fully exercised and no longer remain outstanding. The Form 4 shows zero derivative securities following the transaction, indicating the option position was fully converted into common stock on the transaction date.

When did the Fate Therapeutics options exercised by Robert S. Epstein vest?

The Fate Therapeutics stock options exercised by Robert S. Epstein vested and became exercisable on the date of the company’s 2017 Annual Meeting of Stockholders. This vesting schedule allowed conversion into 25,000 common shares in the reported transaction.